Quarterly report · Q2
4626.TEDINET S100PGNK
Period2022-04-01 → 2022-09-30
Filed2022-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥52.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥98.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥48.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥10.5bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥9.3bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥10.2bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥18.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥9.5bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥10.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥9.5bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥11.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.7bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥7.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥6.8bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥198.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥189.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥184.0bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥105.0bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥103.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥93.4bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥85.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥81.5bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥57.3bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥51.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥57.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥51.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥51.6bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥54.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥12.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥18.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.5bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥133.32 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.86 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.13 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.84 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥63.83 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 47.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.1% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥142m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥30m |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥38.7bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥38.7bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥10.4bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.0bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥51.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥51.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥11.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥52.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥52.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥142m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥11.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥54m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥6m |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥34.9bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥34.9bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥8.3bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥11.8bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥11.8bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.5bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥46.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥46.6bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥9.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥48.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥48.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥54m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥9.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 506
| Item | Context | Value | Unit |
|---|---|---|---|
| Income before income taxes | CurrentYTDDuration | 10203000000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration | 3653000000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration | 3716000000 | JPY |
| Amortization of goodwill ope cf | Prior1YTDDuration | 243000000 | JPY |
| Amortization of goodwill ope cf | CurrentYTDDuration | 246000000 | JPY |
| Loss on retirement of noncurrent assets ope cf | Prior1YTDDuration | 80000000 | JPY |
| Loss on retirement of noncurrent assets ope cf | CurrentYTDDuration | 22000000 | JPY |
| Compensation income ope cf | Prior1YTDDuration | -282000000 | JPY |
| Compensation income ope cf | CurrentYTDDuration | － | JPY |
| Subsidy income ope cf | Prior1YTDDuration | -3000000 | JPY |
| Subsidy income ope cf | CurrentYTDDuration | -32000000 | JPY |
| Increase decrease in net defined benefit asset ope cf | Prior1YTDDuration | -20000000 | JPY |
| Increase decrease in net defined benefit asset ope cf | CurrentYTDDuration | -57000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YTDDuration | 1000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYTDDuration | -9000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YTDDuration | -14000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYTDDuration | -32000000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YTDDuration | 198000000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYTDDuration | -113000000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -39000000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -63000000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 121000000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 197000000 | JPY |
| Decrease increase in consumption taxes refund receivable ope cf | Prior1YTDDuration | 479000000 | JPY |
| Decrease increase in consumption taxes refund receivable ope cf | CurrentYTDDuration | 1102000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | -3027000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | 1120000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -1904000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | 414000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 1315000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | -1500000000 | JPY |
| Other net ope cf | Prior1YTDDuration | -516000000 | JPY |
| Other net ope cf | CurrentYTDDuration | 128000000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 9789000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 15341000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 39000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 66000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -122000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -198000000 | JPY |
| Proceeds from compensation ope cf | Prior1YTDDuration | 282000000 | JPY |
| Proceeds from compensation ope cf | CurrentYTDDuration | － | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -1461000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -2609000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 8528000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 12600000000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -110000000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -33000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 366000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | 410000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -6107000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |